Quantitative polymerase chain reaction (PCR) assay is commonly used to diagnose SARS CoV-2 or COVID-19, but it lacks the ability to account for mutations in the virus over time. SARS CoV-2 has mutated over 200 times since its initial breakout, and further mutations risk altering the gene-based detection "target", reducing the reliability of the test. In this scenario, mutated versions of the virus may not be detected and a second outbreak allowed to spike until the test is updated. Additionally, the binary nature of PCR assay does not allow automated data traceability, which is a critical component for building current and future outbreak prediction models.
JunoCOVID-DX : A viral testing platform with a rapid approach that enables reliable multiplexed detection of current and emerging viral strains and the ability to capture potential mutations. JunoCOVID-DX offers a simplified and non-invasive home-based or isolated sample collection kit. The assay is fast, highly accurate, and offers high volume test (i.e. 96 tests in less than 10 minutes)
Why Use Metabolism-Based Analysis for Detection of COVID-19?
eliminate false positives / negatives due to genetic mutations in the virus
discover the viral impact on individuals, enabling personalized treatment / prevention
rapid results, suitable for mass-scale testing
automated data traceability for tracking and prediction of outbreaks
Miniaturized mobile mass spectrometry-based diagnosis of COVID-19 at scale.
on-site biosample collection
near real-time test results
AI-based pathogen analysis, mapping, and database management
hospitals and clinics
military and government agencies
*Disclaimer: JUNO Rapid SARS CoV-2 Solution is not cleared by the US Food and Drug Administration at the moment.